

COLGATE-PALMOLIVE(INDIA) LTD.

Industry
Bloomberg
BSE Code
NSE Code

Con. Staples
CLGT IN
500830
COLPAL

27 July 2018

RATING	ACCUMULATE
CMP	1084
Price Target	1210
Previous Target	1266
Potential Upside	12%

Stock Info

52wk Range H/L	1285/1017
Mkt Capital (Rs Cr)	29481
Free float (%)	49%
Avg. Vol 1M (,000)	278
No. of Shares (Crore)	27
Promoters Pledged %	NA

Margin expansion continues backed by company's cost efficiency measures

Key Highlights

- ☑ COLPAL's numbers for Q1FY19 remained better than our estimates, overall revenue, which is in line to our estimates, grew by 6% YoY to Rs 1041 cr while PAT growth remain 39% YoY on the back of Rs 34 cr of exceptional gain.
- ☑ The company has reported slightly lower volume growth for Q1FY19. Overall volume grew by 4%(vs our expectation of 6%.) on account of better performance of its natural product portfolio led by Colgate Swarna Vedshakti and Max Fresh.
- ☑ Gross margin for the company has been improving for last 8 quarters while EBITDA margin improved for last four quarters. The company has maintained its streak, EBITDA margin for Q1FY19 improved by 436 bps YoY on the back of cost efficiency measure and rationalization of A&P expenses.

1Q FY19 Result:

Colpal's sales for the quarter, grew by 6% YoY to Rs 1041 cr led by volume growth of 4%(our expectation of 6%). Volume growth remained slightly lower considering weaker base of -5%in Q1FY18. Gross margin improved by 255 bps YoY. EBITDA for this quarter grew by 27% YoY while EBITDA margin improved by 436 bps YoY to 27% on the back of lower COGS, employee ex., other ex. and A&P ex. by 255,24,70 and 87 bps respectively. PAT for this quarter grew by 39% YoY to Rs 190 cr led by exceptional items of Rs 34 cr on account of sale of company's former factory land and building at Aurangabad, Maharashtra.

View and Valuation:

COLPAL's result for Q1FY19 remained better than our expectation. Key positive for this quarter was EBITDA margin improvement, which was expanded by 436 bps YoY. Volume growth for this quarter was 4% which was slightly lower than our expectation of 6%. Going forward, we expect better volume growth for COLPAL considering revival in rural demand (contributes ~40% of sales), better traction from naturals portfolio and increased direct coverage (looking to expand its direct coverage by 25%in FY19). Pricing action and better product mix will ensure stable margin for the company going ahead. Lower capex for coming year will improve company's cash position further which may translate into better dividend payout for shareholders. We value COLPAL at 37 times of FY20e expected EPS and recommend ACCUMULATE with the target price of 1210. We have lowered our EPS estimate for FY20e by 4% considering slightly lower volume growth in Q1FY19.

Key Risks to our rating and target

- ♦ Lower volume growth, considering high competitive intensity.
- ♦ Volume market share in Toothpaste segment.

KEY FINANCIAL/VALUATIONS	FY16	FY17	FY18	FY19E	FY20E
Net Sales	3868	3982	4188	4473	4931
EBITDA	939	944	1112	1276	1390
EBIT	827	810	956	1115	1233
PAT	581	577	673	812	889
EPS (Rs)	21	21	25	30	33
EPS growth (%)	4%	-1%	17%	21%	9%
ROE (%)	56%	45%	44%	52%	54%
ROCE (%)	80%	64%	63%	72%	75%
BV	38	47	56	57	60
P/B (X)	26	20	19	21	19
P/E (x)	47	43	43	39	36

Research Analyst

RAJEEV ANAND

rajeev.anand@narnolia.com

The views expressed above accurately reflect the personal views of the authors about the subject companies and its(their) securities. The authors have not and will not receive any compensation for providing a specific recommendation or view. Narnolia Financial Advisors Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Exhibit: COLPAL's Vol. growth

Volume growth for this quarter was 4% which was slightly lower than our expectation of 6%.




Exhibit: COLPAL's sales and growth

Overall revenue, which is in line with our estimates, grew by 6% YoY to Rs 1041 cr.




Exhibit: Gross and EBITDA Margin

Gross margin improved by 255 bps YoY while EBITDA margin improved by 436 bps YoY to 27%.




Exhibit: PAT and PAT growth

PAT for this quarter grew by 39% YoY to Rs 190 cr led by exceptional items of Rs 34 cr.





Exhibit: Expenses details

EBITDA mar. improved due to lower COGS, employee, other and A&P ex. by 255, 24, 70 and 87 bps respectively.



Financial Details

Balance Sheet

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
Share Capital	14	14	14	27	27	27	27	27
Reserves	476	586	757	1,004	1,247	1,497	1,530	1,620
Networth	490	600	770	1,031	1,274	1,525	1,557	1,647
Debt	-	-	-	-	-	-	-	-
Other Non Current Liab	36	52	65	28	53	55	55	55
Total Capital Employed	490	600	770	1,031	1,274	1,525	1,557	1,647
Net Fixed Assets (incl CWIP)	383	697	923	1,087	1,275	1,304	1,279	1,257
Non Current Investments	37	37	30	31	31	31	31	31
Other Non Current Assets	94	89	59	25	54	39	39	39
Non Current Assets	514	823	1,012	1,228	1,468	1,503	1,478	1,456
Inventory	185	226	252	292	293	227	242	267
Debtors	81	55	70	102	130	201	215	237
Cash & Bank	429	285	254	193	199	305	537	685
Other Current Assets	98	104	113	77	69	80	85	94
Current Assets	793	670	690	775	856	1,061	1,182	1,396
Creditors	467	498	514	552	601	614	656	724
Provisions	65	70	66	49	56	60	64	71
Other Current Liabilities	250	273	286	136	136	102	109	121
Curr Liabilities	781	842	867	943	995	983	1,047	1,149
Net Current Assets	12	(172)	(177)	(168)	(140)	78	135	247
Total Assets	1,307	1,493	1,702	2,003	2,323	2,564	2,660	2,852

Income Statement

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
Revenue from Operation	3,164	3,579	3,982	3,868	3,982	4,188	4,473	4,931
Change (%)		13%	11%	-3%	3%	5%	7%	10%
Other Income	50	50	33	40	41	39	42	58
EBITDA	657	664	822	939	944	1,112	1,276	1,390
Change (%)		1%	24%	14%	1%	18%	15%	9%
Margin (%)	21%	19%	21%	24%	24%	27%	29%	28%
Depr & Amor.	44	51	75	111	133	157	160	157
EBIT	613	613	747	827	810	956	1,115	1,233
Int. & other fin. Cost	-	-	-	-	-	-	-	-
EBT	663	664	780	867	851	995	1,158	1,291
Exp Item	-	64	-	(31)	-	(12)	34	-
Tax	166	188	221	254	274	310	380	403
Minority Int & P/L share of Ass.	-	-	-	-	-	-	-	-
Reported PAT	497	540	559	581	577	673	812	889
Adjusted PAT	497	494	559	603	577	681	789	889
Change (%)		-1%	13%	8%	-4%	18%	16%	13%
Margin(%)	16%	14%	14%	16%	15%	16%	18%	18%

Financial Details

Key Ratios

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
ROE	101%	90%	73%	56%	45%	44%	52%	54%
ROCE	125%	102%	97%	80%	64%	63%	72%	75%
Asset Turnover	2.4	2.4	2.3	1.9	1.7	1.6	1.7	1.7
Debtor Days	9.4	5.6	6.4	9.6	11.9	17.5	17.5	17.5
Inv Days	21.4	23.0	23.1	27.5	26.8	19.8	19.8	19.8
Payable Days	53.8	50.8	47.2	52.1	55.1	53.6	53.6	53.6
Int Coverage								
P/E	17	17	21	47	43	43	39	36
Price / Book Value	18	15	15	26	20	19	21	19
EV/EBITDA	12	13	14	29	26	26	25	23
FCF per Share	33.8	9.8	24.9	15.3	13.5	17.8	31.6	34.9
Div Yield	4%	4%	3%	1%	1%	1%	2%	2%

Cash Flow Statement

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
PBT	663	664	780	867	851	995	1,192	1,291
(inc)/Dec in Working Capital	138	(37)	5	16	31	(89)	23	37
Non Cash Op Exp	42	44	85	107	130	157	160	158
Int Paid (+)	-	-	-	-	-	-	-	-
Tax Paid	(190)	(178)	(206)	(252)	(301)	(347)	(380)	(403)
others	(38)	(35)	(27)	(17)	(23)	6	-	-
CF from Op. Activities	615	457	638	689	688	694	995	1,084
(inc)/Dec in FA & CWIP	(155)	(324)	(300)	(273)	(321)	(209)	(135)	(135)
Free Cashflow	460	134	338	416	367	485	860	949
(Pur)/Sale of Inv	-	10	-	7	-	-	-	-
others	107	133	28	29	(21)	2	-	-
CF from Inv. Activities	(47)	(180)	(272)	(237)	(342)	(207)	(135)	(135)
inc/(dec) in NW	-	-	-	(16)	(14)	(9)	-	-
inc/(dec) in Debt								
Int. Paid	-	-	-	-	-	-	-	-
Div Paid (inc tax)	(428)	(422)	(385)	(376)	(327)	(371)	(779)	(800)
others	-	-	-	-	-	-	-	-
CF from Fin. Activities	(428)	(422)	(385)	(391)	(341)	(380)	(779)	(800)
Inc(Dec) in Cash	140	(145)	(18)	61	5	107	81	149
Add: Opening Balance	156	296	151	133	193	199	456	537
Closing Balance	296	151	132	193	199	305	537	685

Disclosures: The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Narnolia Financial Advisors Ltd. (Formerly Microsec Capital Ltd) (MCL) is a SEBI Registered Research Analyst having registration no. INH300002407. MCL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services, Merchant Banking, Portfolio Management & distribution of various financial products. MCL is a subsidiary company of G Raj & Company Consultants Ltd. (GRaj). MCL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE), Bombay Stock Exchange Limited (BSE) and Metropolitan Stock Exchange Of India Ltd. (MSEI) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) & National Securities Depository Limited (NSDL) and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products. MCL is also SEBI registered Category 1 Merchant Banker & Portfolio Manager. Details of associate entities of MCL is available on the website at www.narnolia.com

No penalties have been levied on MCL by any Regulatory/Statutory authority. MCL, it's associates, Research Analyst or their relative may have any financial interest in the subject company. MCL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. MCL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. MCL and/or its associates may have received any compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, MCL or any of its associates may have: a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d) Subject Company may have been a client of MCL or its associates during twelve months preceding the date of distribution of the research report. MCL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. MCL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MCL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Terms & Conditions: This report has been prepared by MCL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MCL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MCL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement Companies where there is interest

Analyst's ownership of the stocks mentioned NIL

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com.

Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MCL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MCL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MCL & its group companies to registration or licensing requirements within such jurisdictions.

Disclaimer: The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MCL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MCL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sell in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits or lost opportunities that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MCL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MCL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MCL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com. Registered Office Address: Shivam Chambers, 1st Floor, 53, Syed Amir Ali Avenue, Kolkata 700 091. Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-4054 1766.

Registration details Company & Group entities: MCL: SEBI Registration: INZ000166737 (BSE/NSE/MSE); CDSL: IN-DP-424-2007; NSDL: IN-DP-NSDL-245-2005; Research Analyst: INH300002407, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI: ARN 3087

SEBI Registration: BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 G. Raj & Company Consultants Ltd (G RAJ), MCX/NCDEX Commodities Broker: INZ000051636 Microsec Commerce Limited, PMS: INP000005109Narnolia Velox Advisory Ltd., Investment Adviser: INA300005439 Eastwind Capital Advisors Pvt Ltd. (EASTWIND),IRDA License No.134 (Microsec Insurance Brokers Limited), AMFI: ARN 20558, PFRDA NPS POP: 35012016 Narnolia Securities Ltd. (NSL), RBI Registered NBFC:B.05.02568 Narnolia Capital Advisors Pvt. Ltd.